We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 0.27% | 36.85 | 36.85 | 37.10 | 37.05 | 36.25 | 36.40 | 449,522 | 16:35:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 217.94 | 200.13M |
TIDMAPH
RNS Number : 0746O
Alliance Pharma PLC
08 June 2022
For immediate release 8 June 2022
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Total Voting Rights
Alliance Pharma plc (AIM: APH), the international healthcare group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.
As at 31 May 2022 the Company's issued share capital consists of 539,519,338 Ordinary Shares of 1p each.
The total number of voting rights in the Company is 539,519,338 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information:
Alliance Pharma plc + 44 (0)1249 466966 Cora McCallum, Head of Investor Relations & Corporate Communications + 44 (0)1249 705168 ir@allianceph.com + 44 (0)20 7466 Buchanan 5000 Mark Court / Sophie Wills / Hannah Ratcliff alliancepharma@buchanan.uk.com + 44 (0)20 7260 Numis Securities Limited 1000 Nominated Adviser: Freddie Barnfield / Duncan Monteith Corporate Broking: James Black + 44 (0)20 7597 Investec Bank plc 5970 Corporate Finance: Daniel Adams Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the UK, Alliance employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.
For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TVRUPUPUQUPPPGM
(END) Dow Jones Newswires
June 08, 2022 02:01 ET (06:01 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions